Celyad Oncology is advancing a pipeline of proprietary, non-gene edited allogeneic CAR T candidates from its CYAD-200 series, which is underpinned by its shRNA technology platform. Similar to CYAD-101, CYAD-103 is engineered to co-express the chimeric antigen receptor based on NKG2D, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands and the novel inhibitory peptide TIM (TCR Inhibitory Molecule). By clicking on “I accept”, you allow us to place these analytics cookies. We also use cookies that are necessary for the good-functioning of our website. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of … The expression of TIM reduces signaling of the TCR complex by interfering with the CD3ζ component of the TCR complex.CYAD-101 is currently being evaluated, following FOLFOX chemotherapy, in the Phase 1 alloSHRINK trial for the treatment of relapsed/refractory metastatic colorectal cancer (mCRC). The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of … Research Pipeline With many potential new therapies currently in clinical trials, our goal is to be the industry leader in specialty care. Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. Learn more about how to join here: https://celyad.com/2020/08/06/celyad-oncology-reports-half-year-2020-financial-results-and-second-quarter-business-highlights/ $CYADToday, Celyad Oncology reported Q2 2020 financial results and provide recent business highlights. Please check your entries and try again.Our website uses cookies including analytics cookies to help us improve it by collecting statistics on how visitors use our website. In preclinical models, shRNA-mediated knockdown of MICA and MICB expression on NKG2D CAR T cells has shown enhanced in vitro expansion, as well as enhanced in vivo engraftment and persistence, of the CAR T cells, as compared to first-generation NKG2D-based CAR T cells.In January 2020, the Company announced enrollment had begun in the Phase 1 dose-escalation CYCLE-1 trial evaluating the next-generation NKG2D-based CAR T candidate for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes (r/r AML/MDS). You can find more information about the cookies we use by visiting our Cookie Policy. Please check your email for further instructions.Something went wrong. CYAD-02 is an investigational CAR T therapy that engineers an all-in-one vector approach in patient’s T cells to express both (i) the NKG2D chimeric antigen receptor, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed on tumor cells, and (ii) short hairpin RNA (shRNA) technology to knockdown the expression of NKG2D ligands MICA and MICB on the CAR T cells. $CYAD Read the press release: https://lnkd.in/e6udVaw Thanks for subscribing!
Explore highlights of our research and development pipeline across our five areas of focus. The CYCLE-1 trial will evaluate the safety and clinical activity of a single infusion of CYAD-02 produced with the OptimAb manufacturing process following preconditioning chemotherapy with cyclophosphamide and fludarabine. Celyad Oncology is building a diversified pipeline of next-generation allogeneic and autologous CAR T candidates Our website uses cookies including analytics cookies to help us improve it by collecting statistics on how visitors use our website. CYAD-211 is engineered to co-express a B-cell maturation antigen (BCMA) chimeric antigen receptor and a single shRNA hairpin which interferes with the expression of the CD3ζ component of the TCR complex.In July 2020, Celyad Oncology announced FDA Clearance of IND Application for CYAD-211.CYAD-221 is a preclinical, short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of B-cell malignancies. More Info About Celyad ONCOLOGY. We remain focused on discovering scientific breakthroughs to address complex, debilitating diseases.